Subscribe
shutterstock_126388286_j_main
J Main / Shutterstock.com
15 December 2022FeaturesAmericasTimothy Sendek

Amgen v Sanofi: Big Pharma awaits SCOTUS decision

The Supreme Court recently granted a petition for a writ of certiorari in a case concerning an issue of significant importance in the pharmaceutical and chemical technology industry.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Amgen asks Fed Circ to rehear $1.1bn Juno patent suit
16 November 2021   Amgen and two research centres have thrown their support behind Bristol Myers Squibb subsidiary Juno Therapeutics to help restore a $1.1 billion patent judgment against Kite Pharma that was overturned by the US Court of Appeals for the Federal Circuit.
Big Pharma
Sanofi backed by big pharma and more in SCOTUS clash
21 February 2023   Case focuses on the enablement scope of patents | Amici curiae argue Amgen patents are too broad | Pfizer | Eli Lilly | AstraZeneca| Sanofi | Genentech | Bayer | Gilead Sciences| Johnson & Johnson.
Big Pharma
Don’t distort enablement law, Amgen tells SCOTUS
9 March 2023   Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Big Pharma
Amgen asks Fed Circ to rehear $1.1bn Juno patent suit
16 November 2021   Amgen and two research centres have thrown their support behind Bristol Myers Squibb subsidiary Juno Therapeutics to help restore a $1.1 billion patent judgment against Kite Pharma that was overturned by the US Court of Appeals for the Federal Circuit.
Big Pharma
Sanofi backed by big pharma and more in SCOTUS clash
21 February 2023   Case focuses on the enablement scope of patents | Amici curiae argue Amgen patents are too broad | Pfizer | Eli Lilly | AstraZeneca| Sanofi | Genentech | Bayer | Gilead Sciences| Johnson & Johnson.
Big Pharma
Don’t distort enablement law, Amgen tells SCOTUS
9 March 2023   Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.

More on this story

Big Pharma
Amgen asks Fed Circ to rehear $1.1bn Juno patent suit
16 November 2021   Amgen and two research centres have thrown their support behind Bristol Myers Squibb subsidiary Juno Therapeutics to help restore a $1.1 billion patent judgment against Kite Pharma that was overturned by the US Court of Appeals for the Federal Circuit.
Big Pharma
Sanofi backed by big pharma and more in SCOTUS clash
21 February 2023   Case focuses on the enablement scope of patents | Amici curiae argue Amgen patents are too broad | Pfizer | Eli Lilly | AstraZeneca| Sanofi | Genentech | Bayer | Gilead Sciences| Johnson & Johnson.
Big Pharma
Don’t distort enablement law, Amgen tells SCOTUS
9 March 2023   Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
Sandoz wins $137.2m payout for lost profits in generic launch
Dexcom suffers second patent revocation at hands of UPC
Sanofi signs global rights deal to develop rare cancer therapy
WBD to merge with firm to create ‘powerhouse’ practice
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
AstraZeneca unit draws line under Samsung dispute